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Duchenne Muscular Dystrophy (DMD) is a severe muscle degenerative disease, due to absence of dystrophin. There is currently
no effective treatment for DMD. Our aim is to up-regulate the expression level of the dystrophin related gene utrophin in DMD,
complementing in this way the lack of dystrophin functions. To this end we designed and engineered several synthetic zinc
finger based transcription factors. In particular, we have previously shown that the artificial three zinc finger protein named
Jazz, fused with the appropriate effector domain, is able to drive the transcription of a test gene from the utrophin promoter
‘‘A’’. Here we report on the characterization of Vp16-Jazz-transgenic mice that specifically over-express the utrophin gene at
the muscular level. A Chromatin Immunoprecipitation assay (ChIP) demonstrated the effective access/binding of the Jazz
protein to active chromatin in mouse muscle and Vp16-Jazz was shown to be able to up-regulate endogenous utrophin gene
expression by immunohistochemistry, western blot analyses and real-time PCR. To our knowledge, this is the first example of
a transgenic mouse expressing an artificial gene coding for a zinc finger based transcription factor. The achievement of Vp16-
Jazz transgenic mice validates the strategy of transcriptional targeting of endogenous genes and could represent an exclusive
animal model for use in drug discovery and therapeutics.
Citation: Mattei E, Corbi N, Di Certo MG, Strimpakos G, Severini C, et al (2007) Utrophin Up-Regulation by an Artificial Transcription Factor in
Transgenic Mice. PLoS ONE 2(8): e774. doi:10.1371/journal.pone.0000774
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe muscle
degenerative disease, which results from the absence of the
cytoskeletal protein dystrophin. Becker muscular dystrophy (BMD)
is a milder form of the disease, characterized by the presence of
partially functional truncated forms of the dystrophin protein. No
effective treatment for DMD/BMD is yet available [1–2].
Potential therapeutic approaches to DMD include the up-
regulation of the utrophin gene, an ubiquitously expressed
autosomal paralogue of dystrophin [3]. Utrophin displays about
80% homology with dystrophin and is able to perform similar
functions. In particular, both the dystrophin and utrophin proteins
bind members of the dystrophin associated protein complex
(DAPC), forming a link between the extracellular-matrix and the
intracellular actin cytoskeleton, that provides structural integrity to
muscle fibers [4–5]. In adult muscle, utrophin is localized
preferentially at the neuromuscular junction (NMJ) and at
myotendinous junctions, while dystrophin is localized along the
entire length of the sarcolemma [6]. However, in developing
muscle, in regenerating muscle after injury and in mdx (mice
dystrophin-deficient) skeletal muscle, utrophin is also found along
the sarcolemma [7]. It is now well established that ectopic
expression of utrophin prevents muscular dystrophy both in mdx
mice and in utrophin-dystrophin deficient mice [8–13]. Therefore,
many research groups are studying the possibility of up-regulating
utrophin gene expression, either using pharmacological ap-
proaches or by trying to understand the ‘‘natural’’ mechanisms
of increasing utrophin expression in developing, regenerating or
pathological muscle [14–16]. To achieve utrophin up-regulation,
our research group designed and engineered several zinc finger
based synthetic transcription factors, capable of binding and
activating transcription from the utrophin promoter ‘‘A’’ [17–18].
In the large class of proteins capable of binding DNA, zinc finger
proteins have been preferred for the design of artificial
transcription factors on the basis of their structural plasticity and
modularity [19–21]. In particular, a ‘‘recognition code’’ that
relates the amino acids of a single zinc finger to its associated
subsite DNA triplet has been elaborated for several finger domains
[22–30]. Multiple natural/synthetic zinc fingers assembled in
tandem generate multifinger proteins that, when fused to the
appropriate effector domain, can act as transcription factors and
have a wide range of potential applications [31]. Significantly, zinc
finger artificial transcription factors (ZF ATFs) can be used as
therapeutics, for their ability to bind and re-program the
expression of virtually any desired gene. Using the available
‘‘recognition code’’, we previously engineered a gene named Jazz,
encoding for a three-zinc finger peptide designed to specifically
bind the 9 base pair DNA sequence 59-GCT-GCT-GCG-39
present in promoter ‘‘A’’ of both the human and mouse utrophin
genes [32]. We have shown that the chimeric proteins, obtained by
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the transcription of a test gene from both natural and synthetic
utrophin promoters [17].
Here, we show that the ZF ATF ‘‘Vp16-Jazz’’ expressed in
transgenic mice under the control of the myosin light chain
(MLC1) promoter powerfully up-regulates its target gene ‘‘utro-
phin’’ at the chromosomal site. To our knowledge, this is the first
example of a transgenic mouse expressing an artificial zinc finger
transcription factor working on its endogenous target gene.
RESULTS
Structure of the artificial Vp16-Jazz gene
We have previously shown that the chimeric proteins, obtained by
fusing the Jazz zinc-finger gene with the appropriate transcrip-
tional effector domain are able to drive the transcription of a test
gene from both natural and synthetic utrophin promoters [17].
Now, we have engineered a novel Jazz-fusion protein named
‘‘Vp16-Jazz’’ in order to optimize its expression in transgenic
mouse skeletal muscle. The Vp16-Jazz construct (Fig. 1A) contains
the Myosin Light Chain (MLC) promoter/enhancer regions, an
intron region derived from the Simian virus SV40, the strong
transcriptional activation domain Vp16 from herpes simplex virus,
the epitope tag myc and a nuclear localization signal (NLS)
derived from SV40 early genes. The Vp16-Jazz protein specifically
binds the 9 base pairs DNA sequence 59-GCT-GCT-GCG-39
present in the promoter region of both the human and mouse
utrophin genes [32] (Fig. 1B).
Vp16-Jazz expression in transgenic lines
Using the above described Vp16-Jazz construct, several Fo
transgenic mice founders were obtained. The expression of the
transgene was analyzed by western blot on F1 positive mice using
a monoclonal anti-myc antibody. Different levels of Vp16-Jazz
expression were detected in skeletal muscle in several independent
families. Figure 2A reports the level of Vp16-Jazz in transgenic
families tg9 and tg41, that presented optimal transgene expression.
In order to verify the specificity of transgene expression in
families tg9 and tg41, total protein extracts from muscle, heart and
brain were analyzed in western blot. As shown in figure 2B the
Vp16-Jazz is absent in brain, strongly present in skeletal muscle
and slightly present in heart only in family tg9. Other tissues were
also analysed, which confirmed muscle specific expression of
Vp16-Jazz (data not shown).
Vp16-Jazz and utrophin up-regulation
In order to characterize the biological activity of the Vp16-Jazz
protein in transgenic mice chromatin immunoprecipitation experi-
ments(ChIP)wereperformedinmuscleto verifywhether the Vp16-
Jazz transcriptionfactor binds its DNAtarget in vivo inthe context of
the utrophin promoter chromatin infrastructure. In both tg9
(Fig. 3A) and tg41 (data not shown) Vp16-Jazz is able to bind
efficiently and specifically to its DNA target sequence (59-GCT-
GCT-GCG-39) attheendogenousutrophinpromoterchromosomal
site. In the ChIP experiment dystrophin promoter/enhancer region
was used as further specificity control (Fig. 3A, bottom).
Figure 1. Vp16-Jazz and its DNA target sequence. A: Schematic representation of the Vp16-Jazz gene in the pMex-vector, used to generate
transgenic mice. The 9 base pair long Vp16-Jazz DNA target sequence is indicated. B: The nucleotide sequence of the mouse utrophin promoter A.
The Vp16-Jazz DNA target sequence is indicated in bold characters and underlined. The main transcription factor binding sites present in this
promoter region are indicated.
doi:10.1371/journal.pone.0000774.g001
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is effectively up-regulated by the artificial Vp16-Jazz protein. To
this end, we performed a quantitative analysis of utrophin mRNA
levels by real-time PCR. As shown in figure 3B, about 3 to 4 fold
increase of utrophin expression was observed in transgenic mice
compared to the control wild type (wt) mice. As shown, similar
values were obtained using two different normalizing housekeep-
ing-genes (b2-microglobulin and b-glucoronidase) .
To determine whether changes in the expression of utrophin
mRNA were consistent with changes in the protein level a western
Figure 2. Muscle specific expression of Vp16-Jazz in transgenic mice. A: Western Blot analysis of total proteins extracted from the skeletal muscle of
wild type (wt) and transgenic mice derived from two different founders (tg9 and tg41). The expression of Vp16-Jazz transgene was monitored by the
anti-myc monoclonal 9E10 antibody. Detection of a2tubulin was used to normalize the amount of proteins. B: Western Blot analysis of total proteins
extracted from the skeletal muscle, heart and brain of transgenic mice from families tg9 and tg41.
doi:10.1371/journal.pone.0000774.g002
Figure 3. Vp16-Jazz and utrophin up-regulation. A: Vp16-Jazz chromatin immunoprecipitation, performed in skeletal muscle derived from wt mice
and transgenic mice (family tg9) using myc monoclonal antibody/protein G-agarose beads or protein G-agarose beads as a control (no-Ab).
Immunoprecipitates from each sample were analyzed for the presence of utrophin promoter by PCR. A sample representing linear amplification of
the total input chromatin (input) was included (lane 1). As control, samples from transgenic mice were also tested for the presence of dystrophin
promoter sequence. B: Real-time PCR analysis of the utrophin gene expression rate in Vp16-Jazz transgenic mice (tg9 and tg41) and control wt mice.
The gene expression ratio between utrophin and b-glucoronidase (GUS) and b2-microglobulin (b2M) is shown as means6S.D. from three
independent experiments performed in triplicate. C: Western blot of total protein extracts derived from skeletal muscle and heart from wt mice and
Vp16-Jazz transgenic mice (tg9 and tg41) incubated with monoclonal antibody against utrophin. The same membrane was incubated with anti-a-
tubulin monoclonal antibody for loading normalization. D: Relative utrophin expression of wt and transgenic mice (tg9 and tg41) was determined by
densitometric analysis. E: Total protein extracts from skeletal muscle of wt and transgenic mice (tg9 and tg41) were subjected to immunoblotting to
detect the expression levels of the dystrophin and a-sarcoglycan proteins. The anti-a-tubulin and anti-myc antibodies were used to normalize the
protein content and to test the Vp16-Jazz transgene expression respectively.
doi:10.1371/journal.pone.0000774.g003
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shown in figures 3C and 3D, a consistent up-regulation of
utrophin protein levels in skeletal muscle is observed in both
transgenic families, tg9 and tg41, in comparison to wild type
control animals. Notably, as expected, the up-regulation from the
promoter region produces an increase of all the utrophin protein
isoforms in the transgenic lines so far analyzed. Then we
demonstrated that in both transgenic families, tg9 and tg41, and
in wild type control mice dystrophin and alpha-sarcoglycan
protein levels remain invariable in skeletal muscle (Fig. 3E).
Skeletal muscle histological analysis
The histological analysis of the tibialis anterior (TA) stained with
the utrophin antibody revealed a significant increase and
consequent re-localization along the sarcolemma of utrophin
protein in the transgenic mice tg9 (Fig. 4B) and tg41 (data not
shown) compared to wt control animals (Fig. 4A). In order to
further investigate utrophin re-localization, we stained TA with
both anti-utrophin antibody and with Alexa Fluor 488 labeled a-
bungarotoxin to visualize the acetylcholine receptors (AChR) at
the neuromuscular junction. As shown in figure 4C the utrophin
overexpression in transgenic mice tg9 causes a remarkable re-
localization of utrophin protein along the sarcolemma in addition
to its canonical localization at the synaptic regions.
Mechanical response of isolated muscles
The contractile activity of muscles from two month old Vp16-Jazz
transgenic mice, and wt control animals was measured. Isolated
diaphragm and extensor digitorum longus (EDL) preparations of
both hind limbs were examined in vitro by physiological assessment
of muscle force. As shown in figure 4D, both diaphragm and EDL
muscles from transgenic mice show a slight, but constant increase
in muscle strength as compared to wild type littermates. The
increase in muscle strength was similar between the tg9 and tg41
families.
Microarray analysis
To test the wide range genome perturbation induced in vivo by the
artificial zinc finger transcription factor Vp16-Jazz and consequent
utrophin over-expression, microarray analysis was performed,
Figure 4. Effects of Vp16-Jazz in transgenic mice. Immunohistochemistry of Tibialis Anterior (TA) muscle derived from wt (panel A) and transgenic
mice tg9 (panel B) stained with anti-utrophin antibody. Nuclei are counterstained with Hoechst 33258. C: TA from wt and transgenic mice tg9 were
co-stained with anti-utrophin antibody and the a-bungarotoxin-Alexa Fluor to visualize the acetylcholine receptor (AChR) at the neuromuscular
junctions. The anti-utrophin monoclonal antibody reveals an extra-synaptic distribution of utrophin only in transgenic mice. D: Relationship between
contractile response (g) and stimulation frequency (Volts) in diaphragm and EDL muscle preparations obtained from wt, tg9 and tg41 mice. E: Scatter
plots of the DEG with natural log transformed expression values averaged over the 4 replicates. The x–axis reports the mean of the replicates of
transgenic mice, while the y-axis is the mean across the replicates of the control wt mice. Expression values are colour coded with red representing
up-regulated genes in tg9/tg41 and green down-regulated genes compared to wild-type and lines on the graph set at 2-folds differential expression.
doi:10.1371/journal.pone.0000774.g004
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genic tg9 and tg41 mice versus control wt mice. Figure 4E
represents scatter plots of the natural log transformed expression
values of all genes (22690) on the array. Differentially expressed
genes (DEG) found in families 9 and 41 versus control wt mice are
colour coded with lines on the graph set at 2-folds differential
expression.
MATERIALS AND METHODS
Constructs
The Jazz gene fused to a nuclear localization signal region and the
Vp16 activation domain from the herpes simplex virus was sub-
cloned into the pMEX mammalian vector containing the MLC1
promoter/enhancer [33].
Generation of Jazz transgenic mice
The DNA fragment from pMEX-Jazz containing the MLC1
promoter/enhancer and the Jazz-TF as described above was
purified using a Geneclean Kit (Q-BIOgene, MP Biomedicals
Morgan Irvine, CA) and resuspended in injection buffer (10 mM
Tris pH 7,5, 0.1 mM EDTA, 30 mM NaCl) at a concentration of
2 ng/ml.
BDF1 (C57Black66DBA) mice were purchased from Charles
River (Calco, Italy), housed under conventional, controlled
standard conditions and sacrificed by carbon dioxide asphyxiation.
Transgenic mice were generated by microinjecting the trans-
genic DNA into the pronuclei of fertilized eggs derived from
BDF16BDF1 mating, following previously described standard
procedures [34]. The transgenic lines were maintained by crossing
founders (F0) and F1 homozygous mice with wild type BDF1
partners. F1 and F2 transgenic mice and their wild type littermates
of age comprised between 2 and 3 months were used in all
experiments.
Mice Genotyping
Transgene integration in F0 (founders) and transmission in F1/F2
animals was checked by polymerase chain reaction (PCR) analysis.
Genomic DNA was isolated from the tail following standard
procedures. Briefly, tails were incubated overnight at 53uCi n
0.5 ml of tail solution (50 mM Tris-HCl, pH 8, 100 mM EDTA,
1% SDS, 100 mM NaCl) supplemented with 500 mg of Proteinase
K (PCR grade, Roche). DNA was extracted using phenol/
chloroform, precipitated with isopropanol, and dissolved in TE
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA). 1 mg of genomic
DNA was amplified by PCR in 50 ml of reaction buffer containing
0.4 mM dNTPs, 2.5 units of Taq DNA polymerase (Invitrogen
Corporation, Carlsbad, Ca) and 1 mM of the following primers:
primer 1: 59-GTC GCC CCC CCG ACC GAT GTC AGC-39;
primer 2: 59-GGG CGA TCC AGG ATC CCC GGG AAT-39.
PCR reactions were carried out at 94uC for 1 minute, followed by
94uC for 1 minute, 62uC for 2 minutes, and 72uC for 2 minutes,
for a total of 30 cycles.
Immunoblotting
The following mouse monoclonal antibodies were used for
biochemical analysis: anti-Myc (9E10 clone, hybridoma-condi-
tioned medium), anti-utrophin and anti-dystrophin (NCL-DRP2
and NCL-DYS2 respectively, Novocastra, Newcastle, UK), anti-
alpha-sarcoglycan (Ad1/20A6, Vector Laboratories, Burlingame,
CA, USA) anti alpha-Tubulin (Sigma Corporation, St. Louis,
Missouri, USA). For protein extraction, all frozen tissues were
processed in lysis buffer (2% SDS, 5 mM EDTA) supplemented
with 1 mM PMSF and a proteinase inhibitor cocktail (Comple-
te
TM, Roche Diagnostics GmbH Mannheim, Germany), using
a homogenizer (7 mm, OMNI International GLH). Homogenates
were boiled for 10 minutes and clarified by centrifugation for
20 minutes at 120006g. The Quant-iT Protein Assay Kit was
used to measure protein concentration by a Qubit
TM fluorometer
(Invitrogen), according to the manufacturer’s instructions. 25 mgo f
protein extract was electrophoresed through SDS-polyacrylamide
gel (SDS-PAGE) under reducing conditions and transferred onto
nitrocellulose membranes (Schleicher&Schuell). Blots were probed
with a dual immuno-staining with appropriate primary antibody
and horseradish peroxidase-conjugated secondary antibody (Cell
Signaling Technology Inc. Danvers, MA USA). The immunore-
active bands were visualized by chemiluminescence (ECL plus; GE
Healthcare Amersham Buckinghamshire, UK), according to the
manufacturer’s instructions.
Immunohistochemistry
Tibialis anterior (TA) muscles from transgenic and littermate
control mice were fixed for 2 hours in 4% formaldehyde and
cryoprotected in phosphate buffer (PBS)-33% sucrose before
storage at 220uC. Transversal sections (8 mm thick) were obtained
by cryostate at 220uC (LEICA, CM1850UV) and placed onto
polysine-coated microscope slides (Menzel Gmbh&Co). Sections
were permeabilized in PBS-0.2% NP-40 for 15 minutes and
blocked in 5% goat serum. Slides were incubated with anti-
utrophin monoclonal antibody (Novocastra, NCL-DRP2; 1:20
dilution) for 1 hour, washed thoroughly and incubated with Alexa
Fluor 488 goat anti-mouse secondary antibody (Molecular Probes;
1:500 dilution) for 40 minutes. Nuclei were detected by co-staining
sections with Hoechst 33258 (1 mg/ml) (Sigma) for 1 minute. All
incubation steps were carried out at room temperature. Stained
specimens were examined by conventional epifluorescence
microscopy (Olympus BX51; Tokyo, Japan). Images were
captured using a digital camera at 406magnification and merged
using the IAS2000 software.
Unfixed transversal sections (8 mm thick) from TA of wt and
transgenic mice were stained with the a-Bungarotoxin Alexa Fluor
488 conjugated (Molecular Probes), a specific ligand of Acetyl-
choline Receptor (AChR), for 40 minutes at 37uC. Stained
specimens were first examined by epifluorescence microscopy
and then fixed in 4% formaldehyde to perform the utrophin
staining. The Zenon Mouse IgG Labelling Kit (Molecular Probes)
was used to directly conjugate the anti-utrophin monoclonal
antibody with the Alexa Fluor 594, according to the manufac-
turer’s instructions.
Preparation of Total RNA
Total RNA was isolated from skeletal muscle by homogenization
of tissue in Trizol reagent (Invitrogen), according to the
manufacturer’s instructions. The RNA yield was quantified by
a Qubit
TM fluorometer using the Quant-iT assay kit (Invitrogen).
The quality of the RNA was assayed by the Agilent 2100
Bioanalyzer, using the RNA 6000 Nano Assay Kit (Agilent
Technologies).
Real-time PCR analysis
2 mg of total RNA was reverse transcribed using oligo (dT) 12–18
primers and SUPERSCRIPT II (Invitrogen) in a final volume of
20 mla t4 2 uC for 50 minutes. Real-time PCR assays were
performed in a 96-well format using the ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster City,
CA). To obtain the utrophin gene expression rate the amount of
Mice with an Artificial Gene
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b2-microglobulin (b2M) and b-glucoronidase (GUS) to correct for
the differences in the quantity of the cDNA present in the PCR
reactions. Primers and probes for the target gene (UTRN) and for
housekeeping genes were purchased as TaqMan Gene Expression
Assays (AB). The PCR mixtures containing the cDNA template,
the TaqMan Universal PCR master mix (AB), and the primers/
probes in a final volume of 25 ml were analyzed in triplicate, using
the following conditions: incubation at 50uC for 2 minutes,
denaturation at 95uC for 10 minutes and then 40 cycles of
amplification at 95uC for 15 seconds and 60uC for 1 minute. For
each gene amplification, a standard curve was generated using
serial dilutions (200, 40, 8, 1.6 and 0.32 ng) of cDNA from mouse
wild type (negative control). The results were analyzed using
Applied Biosystems analysis software. The data are expressed as
the ratio between UTRN and b2M or GUS mRNA expression. A
minimal number of 9 mice were analyzed for each category.
Chromatin Immunoprecipitation (ChIP) Assay
For one ChIP assay reaction, 100 mg of skeletal muscle from
transgenic and littermate control mice was chopped into small
pieces and cross-linked in 1% formaldehyde at 37uC for
15 minutes. After wash with PBS, tissues were homogenized
(7 mm, OMNI International GLH) in lysis buffer (1%SDS,
1%TritonX-100, 10 mM EDTA 50 mM Tris-Hcl pH8.1) supple-
mented with a proteinase inhibitor cocktail (Complete
TM, Roche),
and incubated for 60 minutes at 8uC. Samples were sonicated to
generate DNA fragments with an average length of about 600 bp,
diluted 10 fold in lysis buffer and centrifuged for 10 minutes at
13,000 rpm at 8uC. Supernatants were pre-cleared with Protein
G-Agarose (Invitrogen) absorbed with sheared salmon sperm DNA
(sSS-DNA, Eppendorf AG Hamburg, Germany) and bovine
serum albumin (BSA, Sigma). At this step, a portion of pre-
cleared sample (,5%) was stored and considered as ‘‘input’’
sample. Immunoprecipitation of Myc-tagged protein-DNA com-
plexes was achieved by incubating the pre-cleared samples
overnight at 4uC with the anti-Myc monoclonal antibody (9E10
clone) and with Protein G-Agarose/sSS-DNA for a further
20 minutes. A ‘‘no-antibody’’ immunoprecipitation was per-
formed as a negative control. All samples were eluted with 1%
SDS, 0.1 M NaHCO3 and the cross-links were reverted by
overnight incubation with 0.2 M NaCl at 65uC. Proteins were
digested with Proteinase K (Roche) and DNA was purified by
phenol/chloroform extraction. The final DNA was subjected to
PCR in 25 ml of reaction buffer containing 0.8 mM dNTPs, 2.5
units of Taq DNA polymerase (Invitrogen) and 1 mM of the
primers specific for the mouse utrophin or dytrophin promoter
respectively, designed as follows:
m-utro forward: 59-GCACGCACGACTGGTTCCGGGAT-
TC-39, m-utro reverse: 59-CTTTGTTCTCCCGGGGAGAC-
CAGTC-39. m-dystro forward: 59-CTGTGGCAGCTTAAGG-
CTTGTTCCCA-39, m-dystro reverse: 59-CATGTCGCCCGA-
GTGTTATTCTGTGC-39.
For utrophin promoter/enhancer amplification PCR reactions
were carried out at 94uC for 45 seconds, 66uC for 30 seconds and
72uC for 30 seconds, for a total of 33 cycles. For dystrophin
promoter/enhancer PCR reactions were carried out at 94uC for
45 seconds, 62uC for 30 seconds and 72uC for 30 seconds, for
a total of 33 cycles.
Mechanical response of isolated muscles
Contractile activity of muscles from two month old Vp16-Jazz
male mice and non-transgenic male littermates, was examined in
vitro by physiological assessment of the muscle force of isolated
diaphragm and extensor digitorum longus (EDL) preparations of
both hind limbs. The muscle preparations were suspended in
a 20 ml bath of oxygenated Krebs solution, maintained at 37uC,
stretched to a tension of 1.0 g and allowed to equilibrate for 30–
60 minutes, changing the superfusion buffer every 15–20 min.
The diaphragm and EDL muscles were directly stimulated using
single stimulations (Electric Stimulatore Digit 3T, Lace Elettro-
nica, Pisa, Italy), carried out with rectilinear pulses of 0.5 msec
duration at 0.05–0.2 Hz, using variable voltage, until the
supramaximal voltage was reached. The mechanical activity of
the muscle was recorded isotonically (7006 isotonic transducer) by
a strain-gauge transducer and displayed on a recording micro-
dynamometer (Unirecord 7050, Basile, Milano, Italy).
Microarray
Total RNA was extracted using Trizol (Invitrogen Corporation,
Carlsbad, Ca) and further purified using the RNeasy mini kit
(Qiagen GmbH, Germany) according to the manufacturer’s
instructions. RNA was quantified using NanoDrop ND-1000
and RNA quality was checked using the Agilent bioanalyzer 2100
(Agilent Technologies Santa Clara, CA). A total of 12 high density
oligonucleotide mouse MOE430A arrays (Affymetrix Toronto,
Canada) were used in this study. All the procedures and
hybridization were performed according to the Genechip
expression technical manual (Affymetrix) as previously reported
[35]. Briefly, 5 mg of RNA was converted to double-stranded
cDNA with Superscript II (Invitrogen) using a T7-(dT)24 primer
(Affymetrix), followed by in vitro transcription to generate biotin-
labelled cRNA probes. Fragmented cRNA (15 mg) was used in
300 ml hybridization cocktail containing spiked controls (Affyme-
trix), 0.1 mg/ml Herring Sperm DNA (Promega Madison, WI,
USA), and 0.5 mg/ml acetylated BSA (Invitrogen). A 200 ml
aliquot of this hybridization cocktail was used on each chip which
was incubated at 45uC for 16 hours rotating at 60 rpm. Following
hybridization, the arrays were processed using a Genechip Fluidics
Station 400 according to the recommended protocols (EukGE-
WS2v4, Affymetrix) of double-staining and post-hybridizations
washes. Fluorescent images were captured using gene Array
Scanner 2500 (Affymetrix). All the experiments were designed and
the information was compiled in compliance with MIAME [36]
guide lines to ensure that the microarray data can be correctly
interpreted and independently verified.
Microarray data analysis
Gene transcript levels were determined from data image files using
algorithms in Gene Chip Operating Software (GCOS1.2,
Affymetrix). Global scaling was performed to compare genes from
chip to chip thus the average signal intensity of the arrays was set
to the same target intensity (TGT=100). The key assumption of
the global scaling strategy is that there are few changes in gene
expression among the arrays being analyzed. All the data quality
controls were carried out and met the Affymetrix quality
assessment guidelines. Data analysis was performed using Data
Mining Tool (DMT 3.1, Affymetrix) and GeneSpring 7.2 (Silicon
Genetics). Robust Multi-Array Average (RMA) expression mea-
surement was also used with the help of probe sequence (GC
content) information (GCRMA) [37] as implemented in BioCon-
ductor R statistics (www.bioconductor.org). Cell Intensity files
were processed into expression values for all the 22,626 probe sets
(transcripts) on each of these arrays following the normalization
step. Differentially expressed genes (DEG) were selected if they
passed the Welch t-test, parametric test, with variance not assumed
Mice with an Artificial Gene
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of the age matched genotypes used in this study.
DISCUSSION
Over the past few years, novel designed zinc fingers with modified
functions led to a variety of applications [29,31]. ZF ATFs permit
to alter expression profiles of genes related to disease, with the aim
of treating pathologies like cancer and genetic diseases [38–40].
Our laboratory has been focused on creating several novel
transcription factors based on modified Cys2-His2 zinc finger
motifs fused to positive or negative regulatory effector domains
[17–18,41–42]. In particular, we engineered ZF ATFs with the
aim of up-regulating the utrophin gene, a possible substitute for
dystrophin in DMD patients. Many research groups are
approaching functional recovery of dystrophic muscle with
different strategies [43–46]. One of the main problem emerged
to perform any dystrophin gene therapy consists in the extremely
large size of its mRNAs, that exceeds the incapsidation limits of
many viral vectors. Recently, the last generation of gutted
adenovirus appears to be able to package very large cDNAs
including dystrophin [47]. In addition dystrophin minigenes,
isolated from patients affected by Becker Muscular Dystrophy can
partially circumvent the problem of dystrophin mRNA large size.
On the other hand, utrophin has the fundamental advantage of
being a protein present in DMD patients and thus being well
tolerated by the immune system of the host. Our strategy is to re-
program the expression of endogenous utrophin by ZF ATFs. We
previously demonstrated that the three zinc finger protein Jazz is
capable of binding and activating transcription from the utrophin
promoter ‘‘A’’ [17]. Then, in order to obtain utrophin up-
regulation in an animal model system, we designed and
engineered a transgenic construct, named Vp16-Jazz, containing
the Jazz zinc finger sequence under the control of the muscle
specific promoter of the myosin light chain. Here, we report that
the transgenic mouse model expresses Vp16-Jazz exclusively in
skeletal muscle, with the exception of a faint expression of the
transgene in the cardiac muscle of family tg9.
Once the chromatin immunoprecipitation experiments demon-
strated that Vp16-Jazz was able to bind efficiently and specifically
in vivo the DNA target sequence at the endogenous utrophin
promoter, Vp16-Jazz ability to re-program expression of utrophin
was investigated. The increase of utrophin mRNA ranged from 3
to 4 fold in mice from different transgenic families as compared
with their non-transgenic littermates. The changes in the
expression of utrophin mRNA were consistent with the increase
in the utrophin protein level demonstrated by western blot analysis
and by immunohistochemistry in the skeletal muscle of transgenic
lines. Moreover, western blot analysis revealed, as expected, that
the up-regulation from the endogenous promoter region mimics
the body’s natural regulatory mechanism, resulting in the
production of several different utrophin isoforms in the transgenic
lines analyzed so far. Interestingly, the tg9 that showed leaky
expression of the transgene in cardiac muscle also displays an
enhanced level of utrophin in the heart. This finding, not only
confirms the efficiency of the artificial Vp16-Jazz in up-regulating
utrophin expression, but also could became useful in future studies
considering that utrophin deficiency worsens cardiac contractile
dysfunction present in dystrophin-deficient mdx mice [48].
Moreover Vp16-Jazz specific expression has a promising
positive effect on muscular strength as demonstrated by in vitro
analysis of the mechanical response of isolated muscles. The
different contractile responses to electric stimulation between
diaphragm and EDL can be easily ascribed to the different nature
and fiber composition of these two muscle [49–50].
Next, the wide range genome perturbation induced in vivo by
Vp16-Jazz and by the consequent utrophin over-expression was
tested by microarray analysis. The analysis of the gene expression
profiles of the transgenic tg9 and tg41 mice versus control wt mice
revealed an irrelevant global transcriptional effect. On the other
hand, microarray analysis doesn’t allow to distinguish between the
transcriptional effects due to Vp16-Jazz transgene and the effects
on global transcription due to the overexpression of the target gene
utrophin.
In conclusion, the main results of our work were: i) the
demonstration that a synthetic transcription factor introduced in
vivo is well tolerated and safe for the health of the transgenic animal
both during development and in adult life; ii) Vp16-Jazz was able
to recognize specifically its DNA target sequence on the utrophin
promoter and to up-regulate utrophin in muscle fibers without
significant non-specific global transcriptional effects; iii) Vp16-Jazz
specific expression has a promising positive effect on muscular
strength as demonstrated by in vitro analysis of the mechanical
response of isolated muscles. Thus the transgenic mouse described
here represents the first example of an animal that could be useful
to validate the use of ZF ATF technology for human gene therapy.
In future work, these Vp16-Jazz transgenic mice will be cross-
bred with mdx mice. The achievement of Vp16-Jazz and Vp16-
Jazz/mdx mice represents an useful animal model for use in drug
discovery and therapeutics.
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